JHS Svendgaard Laboratories receives substantial acquisition disclosure under SEBI takeover code
JHS Svendgaard Laboratories Limited filed a Regulation 31(4) disclosure with NSE, indicating a substantial acquisition of shares. Under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, any acquisition crossing 5% of voting capital or moving from one slab to another triggers mandatory disclosure. The filing suggests an acquirer has breached a disclosure threshold and must now comply with public announcement and open offer requirements unless an exemption applies.
Why it mattersA substantial shareholder has crossed a disclosure threshold under the SEBI Takeover Code; the acquirer must now file a detailed public announcement within prescribed timelines, and the target board must convene to assess potential open offer obligations or exemptions.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Archives - JHS Svendgaard Laboratories Disclosure Filing · official
- NSE Corporate Announcements - JHS Svendgaard Laboratories · official
- SEBI Takeover Regulations, 2011 - Official Text · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026